

Pharmacy & Therapeutics Committee

Meeting Agenda

Thursday, November 21, 2024

7:00 a.m. to 8:45 a.m.

Google Meet joining information

Video call link: <https://meet.google.com/tni-wias-qke>

Or dial: (US) +1 781-342-1136 PIN: 250 067 695#

Persons who wish to address the P&T Committee may contact Bryan Larson at (bslarson@utah.gov) before the meeting or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints.

- 1) Call to order Cole Sloan, PharmD, Chair
 - a) Announce Quorum

- 2) Welcome and Introductions Cole Sloan, PharmD, Chair
 - a) Review and Approval of Minutes
 - b) Housekeeping

- 3) DUR Board Update Ngan Huynh, PharmD

- 4) Review Monet Luloh, PharmD
 - a) Duchenne Muscular Dystrophy
 - i) casimersen (Amondys 45), deflazacort (Emflaza), delandistrogene moxeparvovec (Elevidys), eteplirsen (Exondys 51), givinostat (Duvyzat) golodirsen (Vyondys 53), vamorolone (Agamree), viltolarsen (Viltepso)
 - b) Public Comment
 - c) Committee Discussion/Questions
 - d) Committee Action

- 5) Next Meeting Thursday, February 20, 2025: EGFR Inhibitors

- 6) Adjourned Cole Sloan, PharmD, Chair



Pharmacy & Therapeutics Committee

Meeting Agenda

Tentative Upcoming Pharmacy & Therapeutics Committee Schedule

****Please note: all topics are tentative and subject to change****

Month	Topic	Agents
20 Feb 2025	EGFR Inhibitors	<i>afatinib (Gilotrif), dacomitinib (Vizimpro), erlotinib (Tarceva), gefitinib (Iressa), lapatinib (Tykerb), mobocertinib (Exkivity), neratinib (Nerlynx), osimertinib (Tagrisso), vandetanib (Caprelsa)</i>
15 May 2025	Agents with anti-ALK, RET, and/or MET activity	<i>alectinib, brigatinib, capmatinib ceritinib, crizotinib, lorlatinib, pralsetinib, selpercatinib, tepotinib</i>

The foundation documents used for most reviews are prepared by the University of Utah, College of Pharmacy, and are posted on the P&T Committee website after the meeting. Manufacturers wishing to submit any additional materials they would like reviewed as part of the process to:

Dr. Joanne LaFleur
 College of Pharmacy
 30 South 2000 East
 SLC, UT 84112-5820

All materials must be clearly labeled so that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible), unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.